In a report released today, Chris Cooley from Stephens reiterated a Buy rating on Staar Surgical Company (NASDAQ: STAA), with a price target of $48. The company’s shares closed on Friday at $41.05, close to its 52-week high of $43.60.
According to TipRanks.com, Cooley is a 5-star analyst with an average return of 32.6% and a 76.2% success rate. Cooley covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, DENTSPLY SIRONA Inc, and Endologix Inc.
Currently, the analyst consensus on Staar Surgical Company is a Strong Buy with an average price target of $45.33, which is a 10.4% upside from current levels. In a report issued on August 6, Benchmark Co. also maintained a Buy rating on the stock with a $45 price target.
.
See today’s analyst top recommended stocks >>
Staar Surgical Company’s market cap is currently $1.72B and has a P/E ratio of 535.90. The company has a Price to Book ratio of 33.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STAAR Surgical Co. engages in the development, manufacture, production, market, and trade of implantable lenses for the eye and delivery systems. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Monrovia, CA.